Jean-Michel Bolla

Dr. Jean-Michel Bolla

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2005 in Chemical Reviews
Verified
Journal Article
Closed access
jean Michel Bruneljean Michel Brunel
jean Michel Brunel

1 August 2012 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
SBSilpak Biswas
Silpak Biswas
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
JDJean-Christophe Dubus
Jean-Christophe Dubus
MRMartine Reynaud-Gaubert
Martine Reynaud-Gaubert
JRJean-Marc Rolain
Jean-Marc Rolain
The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial infections is a growing problem worldwide. Colistin was first introduced in 1952 and was used until the early 1980s for the treatment of infections caused by Gram-negative bacilli. In vitro, colistin has demonstrated excellent activity against various Gram-negative rod-shaped bacteria, including multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. Recent clinical findings regarding colistin activity, pharmacokinetic properties, clinical uses, emerging resistance, toxicities and combination therapy have been reviewed. Recent approaches to the use of colistin in combination with other antibiotics hold promise for increased antibacterial efficacy. It is probable that colistin will be the 'last-line' therapeutic drug against multidrug-resistant Gram-negative pathogens in the 21st century.

12 May 2004 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
IHIan P. Holmes
Ian P. Holmes

7 August 2007 in Molecules
Verified
Journal Article
Open access
PDF file
AJAliasghar Jarrahpour
Aliasghar Jarrahpour
DKDariush Khalili
Dariush Khalili
Erik De ClercqErik De Clercq
Erik De Clercq
CSChanaz Salmi
Chanaz Salmi
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
Twelve new bis-Schiff bases of isatin, benzylisatin and 5-fluoroisatin 3a-3l were prepared by condensation of isatin, benzylisatin and 5-fluoroisatin with primary aromatic amines. The chemical structures of the products were confirmed by 1H- and 13CNMR, IR and mass spectral data. The compounds were screened for antiviral activity against a panel of DNA and RNA viruses. Minimum cytotoxic and minimum virusinhibitory concentrations of these compounds were determined. Compounds 3c and 3i were the most cytotoxic in HEL cells. These newly synthesized bis-Schiff bases were also tested for their antibacterial and antifungal activities. They did not display activity against S. cerevisiae (ATCC 28383) or C. albicans (CIP 1180-79).

7 May 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HDHana Douafer
Hana Douafer
VAVéronique Andrieu
Véronique Andrieu
Otto PhanstielOtto Phanstiel
Otto Phanstiel
jean Michel Bruneljean Michel Brunel
jean Michel Brunel

1 May 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
VLVannina Lorenzi
Vannina Lorenzi
AMAlain Muselli
Alain Muselli
ABAntoine FrançoIs Bernardini
Antoine FrançoIs Bernardini
LBLiliane Berti
Liliane Berti
JPJean-Marie Pagès
Jean-Marie Pagès
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
The essential oil of Helichrysum italicum significantly reduces the multidrug resistance of Enterobacter aerogenes , Escherichia coli , Pseudomonas aeruginosa , and Acinetobacter baumannii . Combinations of the two most active fractions of the essential oil with each other or with phenylalanine arginine β-naphthylamide yield synergistic activity. Geraniol, a component of one fraction, significantly increased the efficacy of β-lactams, quinolones, and chloramphenicol.